

## **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for *CYP2C19* and Proton Pump Inhibitor Dosing**

John J. Lima<sup>1</sup>, Cameron D. Thomas<sup>2</sup>, Julia Barbarino<sup>3</sup>, Zeruesenay Desta<sup>4</sup>, Sara L. Van Driest<sup>5</sup>, Nihal El Rouby<sup>2,6</sup>, Julie A. Johnson<sup>2</sup>, Larisa H. Cavallari<sup>2</sup>, Valentina Shakhnovich<sup>7,8,9</sup>, David L. Thacker<sup>10,11</sup>, Stuart A. Scott<sup>12,13</sup>, Matthias Schwab<sup>14,15,16</sup>, Chakradhara Rao S Uppugunduri<sup>17,18</sup>, Christine M. Formea<sup>19</sup>, James P. Franciosi<sup>20,21</sup>, Katrin Sangkuhl<sup>3</sup>, Andrea Gaedigk<sup>7</sup>, Teri E. Klein<sup>3</sup>, Roseann S. Gammal<sup>22,23</sup>, Takahisa Furuta<sup>24</sup>

<sup>1</sup> Center for Pharmacogenomics and Translational Research, Nemours Children's Health, Jacksonville, FL, USA

<sup>2</sup> Department of Pharmacotherapy and Translational Research, and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL, USA

<sup>3</sup> Department of Biomedical Data Science, Stanford University, Stanford, CA, USA

<sup>4</sup> Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA

<sup>5</sup> Departments of Pediatrics and Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA

<sup>6</sup> Division of Pharmacy Practice & Administrative Sciences, University of Cincinnati James Winkle College of Pharmacy, Cincinnati, OH, USA

<sup>7</sup> Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Kansas City and University of Missouri Kansas City School of Medicine, Kansas City, MO, USA

<sup>8</sup> Division of Gastroenterology, Hepatology, and Nutrition, Children's Mercy Kansas City, Kansas City, MO, USA

<sup>9</sup> Center for Children's Healthy Lifestyles & Nutrition, Kansas City, MO, USA

<sup>10</sup> Department of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA

<sup>11</sup> Translational Software, Bellevue, WA, USA

<sup>12</sup> Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

<sup>13</sup> Sema4, Stamford, CT, USA

<sup>14</sup> Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany

<sup>15</sup> Department of Clinical Pharmacology, University Hospital, Tuebingen, Germany

<sup>16</sup> Department of Pharmacy and Biochemistry, University of Tuebingen, Tuebingen, Germany

<sup>17</sup> CANSEARCH Research Laboratory, Department of Paediatrics, Gynaecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland

<sup>18</sup> Oncology-Hematology Unit, Department of Paediatrics, Gynaecology and Obstetrics, Geneva University Hospital, Geneva, Switzerland

<sup>19</sup> Department of Pharmacy Services and Intermountain Precision Genomics, Intermountain Healthcare, Salt Lake City, UT, USA

<sup>20</sup> Division of Gastroenterology, Hepatology and Nutrition, Nemours Children's Hospital, Orlando, FL

<sup>21</sup> Department of Pediatrics, University of Central Florida College of Medicine, Orlando, FL, USA

<sup>22</sup> Department of Pharmacy Practice, MCPHS University School of Pharmacy, Boston, MA, USA

<sup>23</sup> Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA

<sup>24</sup> Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan

**Corresponding Author:**

John J. Lima, PharmD  
Principal Research Scientist Emeritus  
Center for Pharmacogenomics and Translational Research  
Nemours Children's Health  
807 Children's Way  
Jacksonville, FL 32207  
Phone: 352-219-3048  
Fax: 904-697-3799  
Email: [john.lima@nemours.org](mailto:john.lima@nemours.org); [contact@cpicpgx.org](mailto:contact@cpicpgx.org)

**Word Counts:**

Abstract (250 limit): 153  
Text (4,000 limit): 3,435  
References (50 limit): 39  
Figures/tables (7 limit): 2

**Keywords:** CYP2C19, PPI, proton pump inhibitor, omeprazole, lansoprazole, pantoprazole, dexlansoprazole, esomeprazole, rabeprazole, pharmacogenetics, pharmacogenomics, CPIC, metabolism

**Conflicts of Interest:**

JAJ is a consultant to United Health Group for their plans to begin implementing pharmacogenomics in clinical practice; SAS is a paid employee of Sema4, which is a for-profit genetic testing company that offers pharmacogenetic testing. DLT is a paid employee of Translational Software, which is a for-profit genetic testing company that offers pharmacogenetic testing. As an Associate Editor for *Clinical Pharmacology & Therapeutics*, SLV was not involved in the review or decision process for this paper. All other authors declared no competing interests for this work.

**Funding:**

This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264 and U24HG010135), PharmGKB (U24HG010615) and PharmVar (R24 GM123930). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Additional grant funding includes NIH IGNITE Network (NIH U01 HG007269) (JAJ, JJJ, LHC) and U01 HG007762, R01 GM121707 and R01 GM078501 (ZD); GM 0NIH-NCATS UL1TR001427 (LHC); CANSEARCH foundation, Switzerland (CRU); Robert Bosch Stiftung, Stuttgart, Germany (MS); Innovation in Regulatory Science Award 1015006 from the Burroughs Wellcome Fund (SLV); 1K23DK115827-01A1 and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Foundation (VS); and the EU H2020 UPGx grant 668353 (MS).